| Literature DB >> 35790903 |
Kirsty Sands1,2, Maria J Carvalho3,4, Owen B Spiller3, Edward A R Portal3, Kathryn Thomson3,5, William John Watkins3, Jordan Mathias3, Calie Dyer3,6, Chinenye Akpulu3,5,7, Robert Andrews3, Ana Ferreira3, Thomas Hender3, Rebecca Milton3,6, Maria Nieto3, Rabaab Zahra8, Haider Shirazi9, Adil Muhammad8, Shermeen Akif8, Muhammad Hilal Jan8, Kenneth Iregbu7, Fatima Modibbo10, Stella Uwaezuoke11, Grace J Chan12,13, Delayehu Bekele14, Semaria Solomon15, Sulagna Basu16, Ranjan Kumar Nandy16, Sharmi Naha16, Jean-Baptiste Mazarati17, Aniceth Rucogoza17, Lucie Gaju17, Shaheen Mehtar18,19, Andre N H Bulabula19,20, Andrew Whitelaw21,22, Timothy R Walsh3,5.
Abstract
BACKGROUND: In low- and middle-income countries (LMIC) Staphylococcus aureus is regarded as one of the leading bacterial causes of neonatal sepsis, however there is limited knowledge on the species diversity and antimicrobial resistance caused by Gram-positive bacteria (GPB).Entities:
Keywords: Early onset; Epidemiology; Genomics; LMIC; Late onset; Mammaliicocci; Mortality; Neonatal sepsis; Staphylococci
Mesh:
Year: 2022 PMID: 35790903 PMCID: PMC9254428 DOI: 10.1186/s12879-022-07541-w
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.667
Fig. 1Core genome phylogenetic analysis of Staphylococcus aureus including a global contextual analysis. a Detailed core genome characterisation of 100 Staphylococcus aureus isolates (BARNARDS) using Roary (v3.12.0) and Fasttree (v2.1.11). Isolate labels are coloured according to clinical site of origin. The in-silico sequence type (ST) is shown outside of the isolate code (leaf). Presence of mecA, and whether the isolate was classified phenotypically as MRSA (as inferred from oxacillin MIC > 2 mg/l) is denoted by a filled triangle and/or circle respectively. Presence of IS256 is denoted by a filled rectangle. b Core genome characterisation of 351 Staphylococcus aureus isolates, incorporating a European collection [29] using Roary (v3.12.0) and Fasttree (v2.1.11). Coloured ranges in blue represent a S. aureus from the BARNARDS collection. Branch labels are coloured according to country of origin. Symbol represents source of isolate
Fig. 3Temporal frequency and survival curve data for Staphylococcus aureus blood culture isolates. a Stacked bar graph to show the temporal frequency of S. aureus isolates recovered from blood cultures during the BARNARDS sampling, per month. The bar graph is coloured according to the dominant STs, with all other STs being grouped as ‘Other’. b A Kaplan Meier survival plot comparing the four dominant ST groups (with all other STs detected grouped together as a single group called ‘other’) against the age at outcome for the neonate and up to 60 days. Findings are suggestive as the data presented is from a sample size (ST152 n = 15, ST other n = 37, ST5 n = 17, ST6 n = 18 and ST8 n = 13; overall comparison P 0.041)
Fig. 2Core genome phylogenetic analysis of coagulase negative Staphylococcus blood culture isolates. Core genome phylogeny of CoNS isolates displaying key genomic traits for comparison using Roary (v3.12.0) and Fasttree (v2.1.11). Isolate labels are coloured according to clinical site of origin. Clades are highlighted according to species. The in-silico sequence type (ST) is shown outside of the isolate code (leaf). Presence of mecA, and whether the isolate was classified phenotypically as MRSA (as inferred from oxacillin MIC > 2 mg/l) is denoted by a filled triangle and/or circle respectively. Presence of IS256 is denoted by a filled rectangle
Antibiotic susceptibility testing for Gram-positive isolates recovered from blood cultures
| CoNS & | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC(µg/mL) | MIC(µg/mL) | ||||||||
| Antibiotic class | Antimicrobial | Range | MIC50 | MIC90 | Resistance breakpoint | % Resistant | Range | Resistance breakpoint | % Resistant |
| Aminoglycosides | Amikacin | 4- > 32 | 4 | 4 | > 8 | 4.0 | 4– > 32 | > 8 | 18.2 |
| Gentamicin | 0.5– > 8 | 0.5 | > 4 | > 1 | 18.0 | 0.5– > 4 | > 1 | 40.9 | |
| Tobramycin | 0.5– > 8 | 0.5 | > 4 | > 1 | 29.0 | 0.5– > 4 | > 1 | 50.0 | |
| Fluoroquinolones | Ciprofloxacin | 0.5– > 4 | 0.5 | > 4 | > 1 | 20.0 | 0.5– > 4 | > 1 | 40.9 |
| Levofloxacin | 0.5– > 4 | 0.5 | > 4 | > 1 | 15.0 | 0.5– > 4 | > 1 | 40.9 | |
| Glycopeptides | Vancoymcin | 1–2 | 1 | 1 | > 2 | 0.0 | 1– > 8 | > 4 | 2.3 |
| MLS | Azithromycin | 1– > 8 | 4 | > 8 | > 2 | 53.0 | ND | ND | ND |
| Oxazolidinones | Linezolide | 2–8 | 2 | 4 | > 4 | 1.0 | 2– > 16 | > 4 | 2.3 |
| Ansamycins | Rifampicin | 0.03 | 0.03 | 0.03 | > 0.5 | 0.0 | 0.03– > 0.25 | > 0.5 | 13.6 |
| Penicillins | Ampicillin | 2–128 | NA | NA | NA | NA | 2–64 | NA | NA |
| Flucloxacillin | 0.5– > 8 | NA | NA | NA | NA | 1– > 8 | NA | NA | |
| Oxacillin | 1– > 8 | 1 | > 8 | > 2 | 33 | 1– > 8 | 0.25 | 100 | |
| Tetracyclines | Minocycline | 0.25– > 2 | 0.25 | 0.5 | > 0.5 | 7.0 | 0.25– > 2 | > 0.5 | 34.1 |
| Tigecycline | 0.25–0.5 | 0.5 | 0.5 | > 0.5 | 0.0 | 0.25–4 | > 0.5 | 20.5 | |
Minimum inhibitory concentrations of antibiotics were determined by agar dilution. For S. aureus n = 100, except Azithromycin where n = 93. For CoNS and M. sciuri n = 44. Results interpreted according to EUCAST v11 guidelines and documents. The MIC50 and MIC90 were calculated for S. aureus
Fig. 4Neonatal survival curve data for Staphylococcus aureus and pathogenicity markers: MRSA and PVL. Kaplan Meier survival plot comparing a MRSA v MSSA and time to neonatal outcome, and b The presence of virulence factor PVL and time to neonatal outcome censored at the last available follow up appointment
In silico Staphylococcus aureus virulence factors analysed for both onset and outcome of sepsis
| Onset | Outcome | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Function | VF | EOS | LOS | ND | Total | Alive | Deceased | ND | Total |
| Targeting leukocytes | 10 | 19 | 1 | 30 | 17 | 6 | 7 | 30 | |
| 25 | 29 | 12 | 66 | 36 | 14 | 16 | 66 | ||
| 40 | 46 | 14 | 100 | 62 | 18 | 20 | 100 | ||
| Inhibiting host complement systems | 16 | 15 | 5 | 36 | 19 | 8 | 9 | 36 | |
| 39 | 39 | 13 | 91 | 60 | 14 | 17 | 91 | ||
| Death of B cells | 18 | 22 | 8 | 48 | 27 | 10 | 11 | 48 | |
| Formation of aggregates in blood | 3 | 3 | 2 | 8 | 8 | 0 | 0 | 8 | |
| 1 | 2 | 1 | 4 | 4 | 0 | 0 | 4 | ||
| 10 | 5 | 1 | 16 | 12 | 3 | 1 | 16 | ||
| 10 | 5 | 2 | 17 | 12 | 3 | 2 | 17 | ||
| 3 | 3 | 1 | 7 | 6 | 0 | 1 | 7 | ||
| 5 | 8 | 0 | 13 | 12 | 0 | 1 | 13 | ||
| Toxin expression causing injury to endothelium disrupting barrier | 30 | 36 | 13 | 79 | 47 | 14 | 18 | 79 | |
Virulence factors (VF) grouped into reported biological functions [43] and further delineated to show the frequency of S. aureus isolates containing VFs for both onset of sepsis (early onset [EOS] and late onset sepsis [LOS]) and neonatal outcome (not reported deceased from the latest available follow up date, and deceased). ND indicates an unknown onset and/or outcome of sepsis
Fig. 5a Analysis of Mammaliicoccus sciuri recovered from blood cultures and a WGS contextual analysis. A timeline of M. sciuri neonatal sepsis in Pakistan, indicating which were available for whole genome characterisation. The blocks represent an individual case, and are colour coded according to the clinical outcome of sepsis. b A core genome SNP tree for all PP-BB isolates with WGS data available, performed using snippy-gubbins and Raxml (please refer to the text for details on methods) c Comparative phylogenetic tree of all S. sciuri with WGS data available in BARNARDS including the 10 genetically closest strains of M. sciuri from NCBI